Mursla Bio Launches AI Precision Medicine Platform for Non-Invasive Organ-Specific Diagnostics from Blood Samples

Mursla Bio Launches AI Precision Medicine Platform Using Organ-Specific EV Isolation from Blood CAMBRIDGE, England & BOSTON—Mursla Bio, a pioneering company in Extracellular Vesicle (EV) science, has announced the commercial launch of its AI Precision Medicine Platform. This platform is specifically designed to provide non-invasive, organ-specific molecular information from blood, addressing a significant gap in liquid biopsy and precision medicine. The launch coincides with the release of a pre-print paper detailing the first validated method for isolating hepatocyte EVs from plasma, enabling detailed proteomic and miRNA profiling of liver-specific conditions. The AI Precision Medicine Platform excels by isolating and analyzing EVs, which are minute particles secreted by various organs into the bloodstream. Unlike traditional bulk EV isolation methods, Mursla Bio's platform reduces non-target background noise by up to five orders of magnitude, thereby enhancing the clarity and quality of the data. This improvement significantly boosts the performance of predictive models, making them more reliable and broadly applicable. The pre-print, titled “Organ-Specific Isolation of Hepatocyte Extracellular Vesicles from Human Plasma Enables Tissue-Resolved Proteomic and miRNA Profiling,” presents the first comprehensive validation of isolating hepatocyte EVs in humans. The study confirms the liver origin of these EVs through specific proteomic and nucleic acid markers. Key proteomics data was generated in collaboration with Evotec International GmbH, adding robustness to the findings. Patient samples were sourced from University College London, with significant contributions from Professor Brian Davidson, a leading expert in liver disease surgery and clinical research. One of the standout features of Mursla Bio’s Platform is its ability to generate robust, organ-specific multi-omics data using minimal blood volume. This scalability makes it an innovative and practical tool for biomarker discovery and AI-driven diagnostic development. The platform integrates advanced multi-omics workflows, sophisticated AI pipelines, and rigorous IVD translation processes to transform intricate biological signals into clear, regulatory-grade assays. These assays can be deployed on standard clinical instruments using patented methods similar to PCR and ELISA, facilitating widespread clinical adoption. A prime example of the platform's effectiveness is Mursla Bio’s lead clinical program, EvoLiver™, aimed at early detection of hepatocellular carcinoma in cirrhotic patients. Built on multi-omics data from over 300 patients, EvoLiver achieved 86% sensitivity and 88% specificity in detecting early-stage liver cancer. The assay design is fully aligned with IVD standards, and the FDA has granted it Breakthrough Device Designation, recognizing its potential to significantly improve outcomes for at-risk patients. Pierre Arsène, Founder and CEO of Mursla Bio, commented, "Extracellular vesicles serve as nature’s native signal enrichment system, allowing long-distance communication between cells and organs. Our platform leverages this biological mechanism to non-invasively obtain organ-specific, multi-omics data from a small blood sample. By producing structured, biologically labeled datasets optimized for AI, we are poised to revolutionize diagnostic translation. EvoLiver is our first successful application demonstrating real-world clinical impact, and we are now extending access to our platform to advance our pipeline and foster partnerships across other disease areas.” Mursla Bio is actively expanding its pipeline and forging new collaborations. Current research includes organ programs for cardiometabolic, lung, and neurological conditions. The platform's applications extend beyond diagnostics, supporting pharmaceutical development through dynamic patient stratification, therapeutic response monitoring, surrogate markers, and comprehensive molecular phenotyping across complex diseases. For more information about Mursla Bio’s AI Precision Medicine Platform, visit https://mursla.com/ai-precision-platform/. References: 1. Pre-print paper: “Organ-specific isolation of hepatocyte extracellular vesicles from human plasma enables tissue-resolved proteomic and miRNA profiling” 2. Mursla Bio’s EvoLiver surpasses current standards in liver cancer surveillance 3. Mursla Bio receives FDA Breakthrough Device Designation for EvoLiver™ test Contact: Ben Rutter ben.rutter@zymecommunications.com